PT - JOURNAL ARTICLE AU - Eshaghi, Arman AU - Young, Alexandra AU - Wijertane, Peter AU - Prados, Ferran AU - Arnold, Douglas L. AU - Narayanan, Sridar AU - Guttmann, Charles R. G. AU - Barkhof, Frederik AU - Alexander, Daniel C AU - Thompson, Alan J AU - Chard, Declan AU - Ciccarelli, Olga TI - Defining multiple sclerosis subtypes using machine learning AID - 10.1101/19011080 DP - 2020 Jan 01 TA - medRxiv PG - 19011080 4099 - http://medrxiv.org/content/early/2020/04/24/19011080.short 4100 - http://medrxiv.org/content/early/2020/04/24/19011080.full AB - Multiple sclerosis (MS) is subdivided into four phenotypes on the basis of medical history and clinical symptoms. These phenotypes are defined retrospectively and lack clear pathobiological underpinning. Since Magnetic Resonance Imaging (MRI) better reflects disease pathology than clinical symptoms, we aimed to explore MRI-driven subtypes of MS based on pathological changes visible on MRI using unsupervised machine learning. In separate train and external validation sets we looked at a total of 21,170 patient-years of data from 15 randomised controlled trials and three observational cohorts to explore MRI-driven subtypes and test whether these subtypes had differential clinical outcomes. We processed MRI data to obtain measures of brain volumes, lesion volumes, and normal appearing white matter T1/T2. We identified three MRI-driven subtypes who were similar in how they accumulated MRI abnormality. Based on the earliest abnormalities suggested by our model they were called: cortex-led, normal appearing white matter-led, and lesion-led subtypes. In the external validation datasets, the lesion-led subtype showed a faster disability progression and higher disease activity than the cortex-led subtype. In all datasets, MRI-driven subtypes were associated with disability progression (βSubtype=0.04, p=0.02; βStage=-0.06, p<0.001), whilst clinical phenotypes and baseline disability were not. Only the lesion-led subtype showed a significant treatment response in three progressive multiple sclerosis randomised controlled trials (−66%, p=0.009) and in three relapsing remitting multiple sclerosis trials (−89%, p=0.04). Our results show that MRI-driven subtyping using machine learning can prospectively enrich clinical trials with patients who are most likely to respond to treatments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis Investigation was supported (in part) by (an) award(s) from the International Progressive MS Alliance, award reference number PA-1603-08175. We are grateful to all the investigators who have contributed trial data to this study (see the list of investigators in the appendix). We are grateful to Professor Geraint Rees for his comments. We thank Rozie Arnaoutellis, Istvan Morocoz, and Caramanos Zografos for coordinating and organising this study. We thank Jonathan Steel for IT support during this work. This research in part has been conducted using the UK Biobank Resource under Application Number 47233. Data have also been provided in part by the Human Connectome Project, WU-Minn Consortium (Principal Investigators: David Van Essen and Kamil Ugurbil; 1U54MH091657) funded by the 16 NIH Institutes and Centers that support the NIH Blueprint for Neuroscience Research; and by the McDonnell Center for Systems Neuroscience at Washington University. O.C., A.J.T., F.B., and DCA have received funding from the National Institute for Health Research University College London Hospitals Biomedical Research Centre for this work. D.C.A. has received funding for this work from Engineering and Physical Sciences Research Council Grants M020533, M006093, and J020990, as well as the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreements 634541 and 666992.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData in the form of CSV files are available from the main authors to reproduce the results of this study after publication.